Among them, ICBs, represented by programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and cytotoxic T lymphocyte antigen 4 (CTLA4) blockades, have provided promising treatment options for HCC (Qin et al., 2019). This evidence concerns the gene CTLA4 and hepatocellular carcinoma.